Our perspectives
in one place
Topic
Selected filters
ClearNews
See allWHO EMRO RC71: Regional flagship initiative 1: Expanding equitable access to medical products
On 14 October 2024 in Doha, Qatar, IFPMA delivered a statement at the 71st session of the WHO EMRO Regional Committee on the Regional flagship initiative 1: Expanding equitable access to medical products.
Read more77th WHO SEARO Regional Committee: Agenda items 8.2 and 9.6 on NCDs and UHC
On 9 October 2024 in New Delhi, India, IFPMA delivered a statement at the 77th WHO SEARO Regional Committee on Agenda items 8.2 and 9.6: NCDs and UHC.
Read more61st PAHO Directing Council: Access and rational use of strategic and high-cost medicines and other health technologies
On 3 October 2024 in Washington, D.C., IFPMA and FIFARMA delivered a statement at the 61st PAHO Directing Council on a report focused on access and rational use of strategic and high-cost medicines and other health technologies.
Read more61st Directing Council of PAHO: Strategy on epidemic intelligence for strengthening early warning of health emergencies 2024-2029
On 3 October 2024, IFPMA and FIFARMA delivered a statement at the 61st Directing Council of the Pan American Health Organization (PAHO): Strategy on epidemic intelligence for strengthening early warning of health emergencies 2024-2029.
Read moreStatement from IFPMA at UN HLM on AMR 2024
On 26 September 2024, IFPMA submitted the following statement from the floor at the UN High-Level Meeting on AMR. Eight years after the first ever AMR high-level meeting we find ourselves at the precipice of turning the tide. The pharmaceutical industry heard the call to action at the first high-level meeting, and through establishing the...
Read moreInnovative pharmaceutical industry leaders reinforce ethics and business integrity in APEC economies and health sectors
IFPMA, with support and representation from industry leaders, joins stakeholders this week at the 11th Business Ethics for APEC SMEs Forum. This Forum – and the initiative on which it is based – supports the advancement of ethical business practices in the Asia-Pacific economies, with a focus on the health sector and wider health ecosystem....
Read morePublications
See allThe value of prevention for economic growth and the sustainability of healthcare, social care and welfare systems (The European House – Ambrosetti)
Read more
Sustainable access to effective antibiotics
In a new position paper, IFPMA explores some of the challenges in ensuring access to safe and quality-assured antibiotics and propose a set of policy changes for consideration.
Read more
The Value of Reference Agency Assessment Reports in Enabling Regulatory Reliance
Access to information, including the assessment documents of reference national regulatory agencies (NRA), is a key enabler of regulatory risk-based decision making. It promotes an understanding of what was reviewed by the reference NRA, provides a rationale for decision making and promotes confidence and trust. The Centre for Innovation in Regulatory Science (CIRS) has published...
Read more
Expert insights
See all
A framework for trust and global solidarity for the next pandemic
Read more
How empowering healthcare professional voices can build public trust and vaccine uptake
Read more
Adult immunization: Powerful new evidence for a prevention-first mindset
Read moreResources
See allOur Ethos in Action – Decision-Making Framework Toolkit
IFPMA has developed a Five-Phase Decision-Making Framework, grounded in the IFPMA Ethos or value system, to help companies make decisions that balance business objectives and ethical considerations to meet patient needs and the expectations of the medical community, regulators, and society.
Read more
February 2024: Impact of a waiver of intellectual property rights for COVID-19 therapeutics
As discussions on an extension of a waiver of intellectual property (IP) rights on COVID-19 therapeutics continue, latest evidence and data published today explains what the adverse impact of a waiver may be on the entire innovation ecosystem and the consequences it may have on industry’s ability to fight future pandemics.
Read more
Action on NCDs: How the innovative pharmaceutical industry helps bridge the care gap
Read more